Your browser doesn't support javascript.
loading
Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic.
Duncan, Christopher J A; Skouboe, Morten K; Howarth, Sophie; Hollensen, Anne K; Chen, Rui; Børresen, Malene L; Thompson, Benjamin J; Stremenova Spegarova, Jarmila; Hatton, Catherine F; Stæger, Frederik F; Andersen, Mette K; Whittaker, John; Paludan, Søren R; Jørgensen, Sofie E; Thomsen, Martin K; Mikkelsen, Jacob G; Heilmann, Carsten; Buhas, Daniela; Øbro, Nina F; Bay, Jakob T; Marquart, Hanne V; de la Morena, M Teresa; Klejka, Joseph A; Hirschfeld, Matthew; Borgwardt, Line; Forss, Isabel; Masmas, Tania; Poulsen, Anja; Noya, Francisco; Rouleau, Guy; Hansen, Torben; Zhou, Sirui; Albrechtsen, Anders; Alizadehfar, Reza; Allenspach, Eric J; Hambleton, Sophie; Mogensen, Trine H.
Affiliation
  • Duncan CJA; Clinical and Translational Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK.
  • Skouboe MK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Howarth S; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Hollensen AK; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Chen R; Clinical and Translational Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK.
  • Børresen ML; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Thompson BJ; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Stremenova Spegarova J; Clinical and Translational Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK.
  • Hatton CF; Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Stæger FF; Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
  • Andersen MK; Clinical and Translational Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK.
  • Whittaker J; Clinical and Translational Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK.
  • Paludan SR; Clinical and Translational Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK.
  • Jørgensen SE; Section for Computational and RNA Biology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.
  • Thomsen MK; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Mikkelsen JG; Clinical and Translational Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK.
  • Heilmann C; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Buhas D; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Øbro NF; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
  • Bay JT; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Marquart HV; Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • de la Morena MT; Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Klejka JA; Medical Department, Pediatric Section, Dronning Ingrid Hospital, Nuuk, Greenland.
  • Hirschfeld M; Division of Genetics, Department of Specialized Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
  • Borgwardt L; Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
  • Forss I; Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark.
  • Masmas T; Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark.
  • Poulsen A; Department of Clinical Immunology, Copenhagen University Hospital, Copenhagen, Denmark.
  • Noya F; Seattle Children's Hospital, Seattle, WA.
  • Rouleau G; Department of Pediatrics, University of Washington, Seattle, WA.
  • Hansen T; Yukon-Kuskokwim Health Corporation, Bethel, AK.
  • Zhou S; Alaska Native Medical Center, Anchorage, AK.
  • Albrechtsen A; Center for Genomic Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Alizadehfar R; Center for Genomic Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Allenspach EJ; Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Hambleton S; Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Mogensen TH; Division of Allergy & Clinical Immunology, Montreal Children's Hospital, Montreal General Hospital, McGill University, Montreal, Quebec, Canada.
J Exp Med ; 219(6)2022 06 06.
Article in En | MEDLINE | ID: mdl-35442417
Type I interferons (IFN-I) play a critical role in human antiviral immunity, as demonstrated by the exceptionally rare deleterious variants of IFNAR1 or IFNAR2. We investigated five children from Greenland, Canada, and Alaska presenting with viral diseases, including life-threatening COVID-19 or influenza, in addition to meningoencephalitis and/or hemophagocytic lymphohistiocytosis following live-attenuated viral vaccination. The affected individuals bore the same homozygous IFNAR2 c.157T>C, p.Ser53Pro missense variant. Although absent from reference databases, p.Ser53Pro occurred with a minor allele frequency of 0.034 in their Inuit ancestry. The serine to proline substitution prevented cell surface expression of IFNAR2 protein, small amounts of which persisted intracellularly in an aberrantly glycosylated state. Cells exclusively expressing the p.Ser53Pro variant lacked responses to recombinant IFN-I and displayed heightened vulnerability to multiple viruses in vitro-a phenotype rescued by wild-type IFNAR2 complementation. This novel form of autosomal recessive IFNAR2 deficiency reinforces the essential role of IFN-I in viral immunity. Further studies are warranted to assess the need for population screening.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interferon Type I / COVID-19 Limits: Child / Humans Language: En Journal: J Exp Med Year: 2022 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Interferon Type I / COVID-19 Limits: Child / Humans Language: En Journal: J Exp Med Year: 2022 Type: Article